ENVEDA LANDS $311M FOR NATURE-BASED AI DRUG TRIALS

AI DESK■ 1 MIN READ

WED, SEP 23, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Enveda Therapeutics raised $311 million in funding, bringing the AI biotech company's valuation to $2 billion. The capital will accelerate clinical trials for drugs derived from natural compounds.

Enveda uses artificial intelligence to identify drug candidates from natural sources, a process the company says reduces development timelines. The company is currently testing treatments for two applications: skin conditions and weight preservation in patients discontinuing GLP-1 drugs. The latter addresses an emerging market need. GLP-1 medications like Ozempic and Wegovy have driven significant weight loss, but patients often regain weight after stopping treatment. Enveda's candidate aims to maintain those gains. The funding round positions Enveda among a growing cohort of biotech startups leveraging AI to streamline drug discovery. The company's nature-derived approach differentiates it from purely synthetic alternatives, potentially offering safety and efficacy advantages. Enveda will use the capital to expand clinical development, advance its pipeline, and scale operations. The startup has not disclosed timelines for trial completion or regulatory submissions.

■ SOURCES

► TechCrunch

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE STARTUPS DESK

P402AI INFRASTRUCTURE STARTUPS MODAL, BASETEN RAISE FUNDING

Modal Labs and Baseten, two platforms enabling businesses to run AI models, are in advanced funding talks that would significantly boost their valuations. The rounds reflect growing investor appetite for AI infrastructure services.

JUST NOW— AI Desk

P395EMA RAISES $77M SERIES B FOR AI PROCESS AUTOMATION

Ema, an AI agent platform automating corporate processes in HR, IT, and finance, secured $77 million in Series B funding led by Creaegis. The round brings the startup's total funding to $140 million.

2H AGO— AI Desk

P375TEKEVER RAISES $580M ON $6.4B VALUATION

Portuguese surveillance drone maker Tekever secured $580 million in funding led by UC Investments, reaching a $6.4 billion valuation. The raise follows a major £400 million, 10-year contract with UK Ministry of Defence.

5H AGO— AI Desk

P344BESSEMER RAISES $5.75B, SHIFTS FOCUS TO GROWTH STAGE

Bessemer Venture Partners announced $5.75 billion in new funding, with $4 billion allocated to growth-stage investments and $1.75 billion for early-stage companies. The capital deployment signals the firm's strategic pivot toward later-stage startups.

9H AGO— AI Desk

◄ BACK TO NEWS

ENVEDA LANDS $311M FOR NATURE-BASED AI DRUG TRIALS

■ MORE FROM THE STARTUPS DESK

■ SUBSCRIBE TO THE DAILY BRIEF